Spruce Biosciences, Inc. - SPRB STOCK NEWS

Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, reported its Q1 2024 financial results and provided corporate updates. Key highlights include a 45% reduction in ACTH in the CAHmelia-203 study, correlating higher baseline GC doses and drug compliance with better outcomes. The company anticipates topline data from CAHmelia-204 and CAHptain-205 in Q3 2024. Financially, Spruce reported $81.2 million in cash reserves, $2 million in collaboration revenue, and a net loss of $11.6 million, improving from $12.8 million YoY. R&D expenses decreased to $10.3 million, while G&A expenses rose to $4.3 million. Total operating expenses were $14.6 million, down from $15.2 million a year ago. Upcoming milestones include Phase 2 data and an FDA meeting in early 2025.

Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in two upcoming investor conferences in May, featuring Fireside chats and 1x1 meetings. The events will include the JMP Securities Life Sciences Conference on May 13-14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 14-15, 2024. The CEO, Javier Szwarcberg, M.D., M.P.H., will be presenting at these conferences, with webcasts available on the company's investor relations website.

Spruce Biosciences, Inc. announced additional poster presentations at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting baseline characteristics of their CAHptain program for children with congenital adrenal hyperplasia (CAH) and the CAHmelia program for adults with CAH. The company is focused on developing therapies for rare endocrine disorders and will present abstracts at the conference in Chicago, IL.

Spruce Biosciences (Nasdaq: SPRB) is set to present baseline characteristics of its CAHmelia program at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting tildacerfont in adult congenital adrenal hyperplasia management. The presentation aims to address unmet medical needs in pediatric CAH.

Spruce Biosciences, Inc. (SPRB) reports financial results for 2023, highlighting positive data from CAHptain-205 study in pediatric classic CAH and challenges faced in CAHmelia-203 study for adult classic CAH. The company plans to meet regulatory authorities in 2025 for a registrational clinical program. Cost reductions extend cash runway through 2025.

Spruce Biosciences, Inc. (Nasdaq: SPRB) announced topline results from its CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic congenital adrenal hyperplasia (CAH). While CAHmelia-203 did not meet its primary efficacy endpoint, CAHptain-205 showed promising results. The company plans to meet regulatory authorities for a potential registrational program.

Spruce Biosciences, Inc. (SPRB) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO will discuss the development and commercialization of novel therapies for rare endocrine disorders. The live webcast can be accessed on the company's investor relations website, with an archived copy available for 90 days.

Spruce Biosciences, Inc. (Nasdaq: SPRB) has completed enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH), enrolling 100 patients, exceeding the target of 90. The company anticipates reporting topline results in the third quarter of 2024, with plans to meet with regulatory authorities to discuss the potential registrational path forward for tildacerfont. CAHmelia-204 is a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of tildacerfont in reducing glucocorticoid usage in adults with classic CAH.

Spruce Biosciences, Inc. (SPRB) reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). The company's CEO, Javier Szwarcberg, highlighted the significance of hyperandrogenemia and hypercortisolemia within this patient population. Patients in CAHmelia-203 enrolled with mean baseline A4 levels nearly six times above the upper limit of normal on a mean baseline daily glucocorticoid (GC) dose of 27 mg hydrocortisone equivalents (HCe). On the other hand, patients in CAHmelia-204 enrolled with a mean baseline daily GC dose of 35 mg HCe and suppressed levels of A4. Spruce Biosciences looks forward to reporting topline results from CAHmelia-203 in March, followed by CAHmelia-204 in the third quarter.